Table 2.

Clinical trials in ALL that are currently recruiting

Phase	Sponsor	Clinical trial identifier	Condition	Concomitant medication	Primary end point
I/II	Amgen	NCT02412306	Japanese adults with R/R ALL		Phase I: DLT, II: CR
II	M.D. Anderson cancer center	NCT02877303	Primary diagnosed Ph-neg. ALL ≥14 years	Sequentially with Hyper-CVAD	RFS
II	M.D. Anderson cancer center	NCT02458014	Adult patients in CR1 or CR2 with MRD nonresponse or relapse	None	RFS
II	M.D. Anderson cancer center	NCT02807883	Maintenance after allogeneic HSCT in adults	None	Toxicity, GvHD, graft failure
II	National Cancer Institute	NCT02143414	Primary diagnosed patients ≥65 years ± Ph+	Combination chemotherapy or dasatinib + prednisone	DLT, OS
III	Amgen	NCT02393859	Pediatric patients with 1. High risk relapse	Comparison with standard combination chemotherapy	EFS
III III	National Cancer Institute National Cancer Institute	NCT02101853 NCT02003222	Patients from 1 to 30 years with relapsed ALL Primary diagnosed Ph-neg. adults	Comparison with standard combination chemotherapy ± HSCT ± standard combination chemotherapy	DFS OS

Abbreviations: CR, complete remission; CVAD, course A: cyclophosphamide, vincristine, dexamethasone, course B: methotrexate, cytarabine; DLT, dose limiting toxicity; EFS, event-free survival; GvHD, graft vs host disease; HSCT, hematopoietic stem cell transplantation; MRD, minimal residual disease; OS, overall survival; Ph, Philadelphia chromosome; RFS, relapse-free survival; R/R ALL, relapsed or refractory acute lymphoblastic leukemia.